Inozyme Pharma’s (INZY) “Outperform” Rating Reiterated at Wedbush

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research report issued on Monday,RTT News reports. They currently have a $7.00 price objective on the stock, down from their prior price objective of $12.00.

Several other research firms also recently commented on INZY. Raymond James began coverage on Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective on the stock. Piper Sandler cut their price target on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Wells Fargo & Company lowered their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Finally, HC Wainwright raised their target price on shares of Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $17.78.

Inozyme Pharma Trading Down 4.8 %

Shares of NASDAQ INZY traded down $0.06 during mid-day trading on Monday, reaching $1.10. The company had a trading volume of 189,426 shares, compared to its average volume of 506,952. The stock has a market cap of $70.34 million, a price-to-earnings ratio of -0.70 and a beta of 1.32. Inozyme Pharma has a 52 week low of $1.04 and a 52 week high of $7.80. The business’s 50-day moving average is $1.62 and its 200-day moving average is $3.36. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Inozyme Pharma (NASDAQ:INZY) last issued its earnings results on Monday, March 10th. The company reported ($0.42) EPS for the quarter, hitting analysts’ consensus estimates of ($0.42). Equities analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Two Sigma Investments LP purchased a new position in Inozyme Pharma in the fourth quarter worth $88,000. Two Sigma Advisers LP boosted its position in shares of Inozyme Pharma by 223.9% in the 4th quarter. Two Sigma Advisers LP now owns 78,700 shares of the company’s stock worth $218,000 after purchasing an additional 54,400 shares in the last quarter. Sanofi purchased a new position in Inozyme Pharma during the 4th quarter worth $1,228,000. Shay Capital LLC acquired a new position in Inozyme Pharma during the 4th quarter valued at about $148,000. Finally, ProShare Advisors LLC purchased a new stake in Inozyme Pharma in the fourth quarter valued at about $49,000. Institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.